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Firmly anchored photosensitizer Chlorin e6 to
layered double hydroxide nanoflakes for highly
eﬃcient photodynamic therapy in vivo†
Li Yan,ab Zhigang Wang,c Xianfeng Chen,*d Xiao-Jun Gou,a Zhenyu Zhang,b
Xiaoyue Zhu,b Minhuan Lan,b Wei Chen,b Guangyu Zhuc and Wenjun Zhang*b
In using nanomaterials for advanced photodynamic therapy, it is
important to improve surface modification to increase stability,
minimize non-specific loss of drugs in blood circulation, enhance
the photostability of photosensitizers, and achieve highly eﬃcient
intracellular uptake. In this report, we for the first time covalently
conjugate photosensitizer Chlorin e6 (Ce6) to polyethylene glycol
modified layered double hydroxides and produce hybrid nano-
flakes. These nanoflakes display many superior characteristics and
lead to excellent in vivo photodynamic therapeutic eﬃciency and
safety profiles.
Photo-induced therapy, like photodynamic therapy (PDT), is a
promising approach for cancer treatment, because of its high
eﬃciency, low toxicity and minimal invasion.1–9 In a typical
PDT treatment, photosensitizers (PSs) play a key role by generating
singlet oxygen (1O2) to induce the apoptosis/necrosis of local cancer
cells.10,11 Chlorin e6 (Ce6) is a widely used PS molecule.12,13 Similar
to many other conventional PS molecules, Ce6 suffers from major
limitations such as low solubility, intracellular delivery efficiency,
and photostability. To address the problems of free drugmolecules,
nanomaterials have been developed and have attracted great
attention in cancer therapy.14–20 For example, polymer nano-
particles, upconversion nanoparticles, gold nanostructures,
and silica nanoparticles have been employed in delivering PS
molecules.21–24 Among the choices, layered double hydroxide
(LDH) nanomaterials have been very attractive due to their
superior merits including good biocompatibility, biodegradability
like biomolecule based nano-carriers,25–28 and pH sensitive drug
release characteristics.29–44 Despite these advantages, there are
also issues when LDH nanoparticles are employed in delivering
PS molecules for photodynamic therapy. In particular, owing to
the lack of functional groups on the surface, these nanomaterials
are not stable in blood circulation. Additionally, drug molecules
are commonly loaded into the interlayers through an ion-
exchange method. In such a system, drug molecules can very
easily and quickly release out once in blood circulation, thereby
causing undesirable side effects and reduced therapeutic efficacy.
To overcome these drawbacks, in this report, we create new
LDH–Ce6 hybrid nanoflakes by functionalizing the surface of
LDH nanoparticles and covalently conjugate Ce6 molecules.
Using this strategy, Ce6 molecules are firmly anchored to the
stabilized LDH matrix. In this system, Ce6 molecules tightly
bind to LDH with very slow release profiles, avoiding pre-
mature release of the drug molecules in blood and ensuring
their efficient delivery to tumors. Once there, the acidic
environment in the tumors will significantly expedite the drug
release for powerful PDT.
The schematic of the preparation of LDH–Ce6 hybrid nano-
flakes is illustrated in Scheme S1 (ESI†). The interlayer spacing
of LDH nanoparticles was first expanded by addition of sodium
dodecyl sulfate (SDS) during preparation.45 Through this
approach, the interlayer spacing of LDH nanoparticles
increases from 0.77 to 2.6 nm, indicated by the (003) diffraction
peak’s shift from 11.51 to 3.41 in the X-ray diffraction (XRD)
pattern (Fig. S1a, ESI†). In Fourier transform infrared (FTIR)
spectra, the appearance of SDS’ peaks of SDS expanded LDH
nanoparticles confirms the successful incorporation of SDS
into LDH (Fig. S1b and S2, ESI†). Next, Ce6 molecules were
covalently linked to (3-aminopropyl)triethoxysilane (APTES) in
the presence of N-(3-dimethylaminopropyl)-N-ethylcarbodiimide
hydrochloride (EDC) as a catalyst (Scheme S1, ESI†). Finally, to
get LDH–Ce6 hybrid nanoflakes, APTES linked Ce6 was added to
methylene chloride solution containing SDS expanded LDH
nanoparticles and N-cetyl-N,N,N-trimethylammonium (CTAB)
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followed by centrifugation. As shown in Fig. S2 (ESI†), the
as-prepared LDH–Ce6 hybrid nanoflakes contain FTIR peaks of
both LDH and Ce6, demonstrating the successful attachment of
Ce6 to the LDHmatrix. Moreover, the two broad peaks at around
1000–1200 cm1 correspond to Si–O–Si vibration, indicating the
covalent attachment of APTES to the LDH matrix (Fig. S1b,
ESI†).46 Fig. 1a and b shows the transmission electron micro-
scopy (TEM) images of LDH–Ce6 hybrid nanoflakes with a size of
about 20–50 nm. These nanostructures were further characterized
by atomic force microscopy (AFM) (Fig. 1c and d). The morphology
of LDH–Ce6 hybrid nanoflakes is very similar to what we obtained
by TEM. The thickness is about 10 nm, indicating that the pristine
LDH structure was partially exfoliated to hybrid nanoflakes.
The diminished diffraction peaks in the LDH–Ce6 XRD pattern
(Fig. S1a, ESI†) also confirm the destruction of the original layered
structure of the pristine LDH nanoparticles.
After successfully fabricating LDH–Ce6 hybrid nanoflakes,
we studied their optical properties and ability of singlet oxygen
production. Fig. S3 (ESI†) shows the absorbance spectra of free
Ce6 and LDH–Ce6 hybrid nanoflakes. After Ce6 molecules are
incorporated into LDH, a slight red-shift of its absorption peaks
can be observed. Other than the trivial shift, the absorption peaks
are largely maintained, indicating that the whole fabrication
process does not destruct the optical properties of Ce6 molecules.
To demonstrate that the LDH–Ce6 hybrid nanoflakes have the
potential for photodynamic therapy, we used 1,3-diphenyliso-
benzofuran (DPBF) as a chemical probe to detect generated singlet
oxygen (1O2). As shown in Fig. S4a (ESI†), both Ce6 and LDH–Ce6
hybrid nanoflakes can effectively generate 1O2 at pH 7.4 and pH
5.0, which is indicated by the dramatically decreased absorption
intensity of DPBF. It is clear that the hybrid nanoflakes maintain
their ability of singlet oxygen generation. Particularly, at pH 5.0,
the production of singlet oxygen is more or less similar to that
from free Ce6 molecules. In great contrast, the conventional
method of loading Ce6 into the interlayers of LDH nanoparticles
by ion-exchange causes dramatically decreased 1O2 generation
efficiency.31
Furthermore, we studied the photostability of Ce6 and
LDH–Ce6 hybrid nanoflakes by exposing both materials to
650 nm light illumination for different periods of time (Fig. S5,
ESI†). When Ce6 solution is exposed to the light, the absorbance
intensity rapidly falls. This suggests that serious photobleaching
has occurred to the PS molecules. In comparison, the decreasing
rate of the absorbance of the hybrid nanoflakes is much slower.
From these observations, it is apparent that Ce6 can be protected
by LDH hybrid nanoflakes and therefore the photostability is
improved. To further demonstrate the enhanced photostability of
LDH–Ce6 hybrid nanoflakes, we also studied the 1O2 generation
ability of free Ce6 and LDH–Ce6 hybrid nanoflakes after exposing
both materials to 650 nm light irradiation for 30 min before the
test (Fig. S4b, ESI†). Very attractively, LDH–Ce6 can still effectively
yield 1O2. In sharp contrast, free Ce6 molecules nearly lose their
ability to produce 1O2. This test provides strong evidence that
LDH–Ce6 hybrid nanoflakes are much more stable than free Ce6
under light irradiation, which makes LDH–Ce6 hybrid nanoflakes
very promising for photodynamic therapy.
After having explored that LDH–Ce6 hybrid nanoflakes
preserve their ability to yield singlet oxygen and exhibit much
higher photostability than free Ce6, we then investigated
whether Ce6 is firmly anchored to the LDH matrix in biological
environments. In this experiment, LDH–Ce6 hybrid nanoflakes
were dispersed in pH 7.4 phosphate buffered saline (PBS).
During the observation period of 72 hours, only a small fraction
of Ce6 is released, implying that most Ce6 molecules robustly
bind to LDH nanostructures at pH 7.4 (Fig. S6, ESI†). Thus, we
prove that Ce6 molecules strongly bind to LDH nanostructures
and remain stable at pH 7.4 with minimal liberation. In sharp
contrast, when drug molecules are loaded into LDH nano-
particles using an ion-exchange method, more than 60% can
be released during the first 24 hours.47 This leads to serious
non-specific loss of Ce6 in blood transport, resulting in low
therapeutic efficiency and high toxicity.
Besides that LDH can increase the photostability and stability
of Ce6 in biological environments, enhanced cellular uptake
would be another advantage of the LDH based system. Fig. S7
(ESI†) presents the confocal microscopy images of A549 cells
incubated with free Ce6 and LDH–Ce6 hybrid nanoflakes for
4 hours and 24 hours. From these pictures, very low fluorescence
signals can be detected from A549 cells incubated with free Ce6
for 4 and 24 hours, showing that not many free Ce6 molecules
penetrate the cell membrane and are delivered into cells. In
comparison, strong fluorescence signals are observed for the
cells treated with LDH–Ce6 hybrid nanoflakes for the same
duration. These results unambiguously imply that the LDH–Ce6
hybrid nanoflakes can efficiently transport Ce6 molecules to cells.
We subsequently analyzed the ability of LDH–Ce6 hybrid nano-
flakes to generate 1O2 within cells by measuring cellular reactive
oxygen species (ROS). In this experiment, A549 cells were
incubated with Ce6 and LDH–Ce6 hybrid nanoflakes for 4
and 24 hours followed by confocal microscopy observation
(Fig. 2 and Fig. S8–S10, ESI†). It is very obvious that only a very
small amount of ROS can be detected from A549 cells incu-
bated with free Ce6 for both 4 and 24 hours, because a trivial
Fig. 1 (a and b) TEM images of LDH–Ce6 hybrid nanoflakes. (c) AFM
image of LDH–Ce6 hybrid nanoflakes. (d) The thickness analysis of LDH–Ce6
hybrid nanoflakes along the marked line in (c).
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amount of Ce6 is delivered into cells when free Ce6 molecules
are applied. On the contrary, in the two groups of A549 cells
mixed with LDH–Ce6 hybrid nanoflakes, the ROS production is
very high, marked by bright fluorescence. This significantly
elevated ROS production is likely due to the enhanced cellular
internalization of LDH–Ce6 hybrid nanoflakes.
The phototoxicity of Ce6 and LDH–Ce6 hybrid nanoflakes
was then studied to assess their cancer cell killing efficacy
(Fig. 3a and b and Fig. S11, ESI†). Similar to the methodology in
cellular uptake and ROS production analysis, A549 cells were
incubated with Ce6 and LDH–Ce6 hybrid nanoflakes for 4 and
24 hours under light illumination. When A549 cells are incubated
with free Ce6 for 4 hours, the cell viability is not negatively
affected, even at the highest concentration of 5 mg mL1. When
the incubation time of Ce6 is extended to 24 hours, the viability of
A549 cells decreases below 10% at a concentration of 5 mg mL1.
This can be explained by the observation of cellular uptake and
ROS detection: incubation of 4 h is not enough for free Ce6
molecules to be delivered into cytoplasm, and therefore negli-
gible cellular ROS was generated to kill the cells. In comparison,
the viability of A549 cells treated with LDH–Ce6 hybrid nano-
flakes containing the same concentration of Ce6 for 4 hours
sharply falls below 50%. This means that, with the aid of LDH,
Ce6 starts to show obvious function at a much earlier time.
We also studied the photostability of our fabricated
LDH–Ce6 hybrid nanoflakes with free Ce6 as a reference by
measuring their cell killing efficacy. In this study, free Ce6 and
LDH–Ce6 hybrid nanoflakes were irradiated under 650 nm light
for 30 minutes before incubation with A549 cells. After the
pre-irradiation, the materials were incubated with cells for
4 and 24 h followed by MTT assay. Within our expectation,
free Ce6 did not show any phototoxicity to A549 cells, even in
the case of 5 mg mL1 concentration and 24 h incubation. These
data are consistent with our previous discovery that Ce6 is not
stable upon light exposure and the ability of 1O2 can be almost
lost with only 30 minutes of light irradiation. Attractively,
LDH–Ce6 hybrid nanoflakes can still maintain their ability to
kill cancer cells. As shown in Fig. 3b, the cell viabilities still
display dependency on the dose of LDH–Ce6. When the
concentration of the hybrid nanoflakes increases from 0.04 to
5 mg mL1, nearly all cells are killed. Collectively, these results
show that LDH–Ce6 hybrid nanoflakes exhibit excellent cancer
cell killing efficiency and also confirm their high photostability.
To demonstrate the therapeutic eﬃcacy of our LDH–Ce6
hybrid nanoflakes in vivo, their antitumor activity was assessed
on 4T1 tumor bearing BALB/C mice. In order to prolong in vivo
circulation time and reduce non-specific loss of LDH–Ce6,
we co-modified the surface of our LDH nanostructures with
PEG-carboxyl molecules (Mw = 5000) simultaneously with Ce6
(Fig. S12, ESI†). The mice were intravenously injected with PBS,
the LDH–Ce6 mix (LDH loaded into the interlayers of LDH
through ion-exchange), free Ce6, LDH–Ce6 hybrid nanoflakes
on days 1, 4 and 7, and exposed to 650 nm light on days 1, 3, 5,
7, 9 and 11. The results are summarized in Fig. 4a. Attractively,
it can be seen that LDH–Ce6 hybrid nanoflakes achieve signifi-
cantly improved tumor growth inhibition as indicated by the
size reduction to 13.4%, 14.3% and 26.9% of the tumor volume
in the PBS, LDH–Ce6 Mix, free Ce6 treated groups, respectively.
Moreover, we found that the LDH–Ce6 mix does not seem to
have therapeutic efficacy with intravenous injection. This sharp
Fig. 2 Laser scanning confocal microscopy images of H2DCFDA-stained
A549 cells after 4 (a–f) and 24 (g–l) hours of incubation with Ce6 and
LDH–Ce6 hybrid nanoflakes, and followed by 10 minutes of 650 nm
irradiation.
Fig. 3 The phototoxicity of free Ce6 (Ce6), LDH–Ce6 hybrid nanoflakes
(LDH–Ce6), 30 minutes 650 nm light pre-irradiated free Ce6 (Ce6
(30 min+)) and 30 minutes 650 nm light pre-irradiated LDH–Ce6 hybrid
nanoflakes (LDH–Ce6 (30 min+)). A549 cells were incubated for 4 hours
(a) and 24 hours (b), followed by 10 minutes of light irradiation.
Fig. 4 (a) Tumor growth curves and (b) the body weight evolution of 4T1
tumor bearing BALB/C mice after intravenous injection with diﬀerent
formulations on days 1, 4, and 7 and sacrifice on day 15 (the arrows on
the X-axis indicate tail vein injection on days 1, 4 and 7; * indicates light
irradiation on days 1, 3, 5, 7, 9 and 11).
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difference demonstrates that our LDH–Ce6 hybrid nanoflakes
can overcome the major disadvantages of the traditional
LDH–PS system which loads PS simply by ion-exchange.
LDH–Ce6 without irradiation seems to also have some thera-
peutic efficacy. The reason might be that all mice are in an IVC
(Individually Ventilated Cages) animal house with white room
light and it may help to generate a small amount of ROS
(Fig. S13, ESI†). In addition, the mice treated with LDH–Ce6
hybrid nanoflakes steadily gain body weight, which partially
indicates that the hybrid nanoflakes have minimal side-effects.
Moreover, no obvious organ damage was found by hematoxylin
and eosin (H&E) staining of major organs after the mice were
treated with LDH–Ce6 hybrid nanoflakes (with 650 nm light
irradiation), which further confirms the biosafety of LDH–Ce6
hybrid nanoflakes (Fig. S14, ESI†).
In summary, we created an approach to covalently bond Ce6
molecules to LDH with PEG surface modification for highly
eﬃcient anticancer photodynamic therapy. The LDH–Ce6
hybrid nanoflakes have the ability to generate singlet oxygen,
high photostability, efficient intracellular delivery, and ultimately
superior in vitro and in vivo photodynamic therapeutic efficacy
with minimal side-effects.
This work was financially supported by the General Research
Fund of Hong Kong (GRF No. 11338516), the National Natural
Science Foundation of China (No. 51672230 and 51372213), the
School of Engineering of University of Edinburgh, and the
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